Clinical Trials Logo

Glaucoma clinical trials

View clinical trials related to Glaucoma.

Filter by:
  • Withdrawn  
  • Page 1 ·  Next »

NCT ID: NCT05043831 Withdrawn - Ocular Hypertension Clinical Trials

Direct Selective Laser Trabeculoplasty in Ethnic Chinese Population The Zhuiguang Trial

Start date: October 15, 2021
Phase: N/A
Study type: Interventional

The objective of this study is to evaluate the effectiveness (Intra-Ocular Pressure lowering) and safety of Direct Selective Laser Trabeculoplasty (DSLT) in ethnic Chinese subjects with Primary Open Angle Glaucoma or Ocular Hypertension.

NCT ID: NCT04781283 Withdrawn - Glaucoma Clinical Trials

Study Comparing the Kinetics of Endothelial Cell Loss Associated With the XEN® Implant Versus Traditional Filtering Surgery for Glaucoma

CINEXEN
Start date: November 15, 2021
Phase: N/A
Study type: Interventional

Glaucoma is a blinding optic neuropathy that affects 60 million people worldwide. Of all the types of existing glaucoma, primary open-angle glaucoma is the most common etiology. The therapeutic arsenal today includes drug lowering treatments, lasers and surgery. The most frequent glaucoma surgeries are, in France, trabeculectomy and non-perforating deep sclerectomy (NPDS). These are two filtering surgeries whose principle is to lower the intra ocular pressure (IOP) by creating an evacuation path of the aqueous humor from the anterior chamber (AC) of the eye to the space subconjunctival creating a filtration bubble (FB). These two procedures are currently considered the gold standard. They can be performed alone or at the same time as cataract surgery. The short-term complications encountered with these techniques are early hypotonia and its attendant complications (choroidal detachment, hypotonic maculopathy, hemorrhages, etc.), the most common cause of which is conjunctival leakage from the bubble. In the medium term, increases in blood pressure with deep AC testify to a scleral flap that is too tight which may require suture lysis. Finally, the problems of excessive conjunctival-Tenon healing concern 25 to 30% of those operated on and are responsible for the majority of late blood pressure increases. In the longer term, the most common complication is cataracts; the rarest, but most serious complication is infection of BF, which occurs more readily when the walls of the FB are ischemic or even perforated. It can be complicated by an extremely serious endophthalmitis. A new minimally invasive therapeutic option has been developed limiting per- and post-operative complications. Unlike traditional techniques which present an ab externo approach, the ab interno approach of the new technique proposed consists of the implantation of a tube of collagen 6 mm in length and 45 µm of light called Xen® through the AC .

NCT ID: NCT04676126 Withdrawn - Glaucoma Clinical Trials

Augmented Macular Pigment-containing Nutraceutical and Central Visual Function

Start date: May 2021
Phase: Phase 4
Study type: Interventional

The purpose of this study is to prospectively analyze changes in macular pigment optical density and dermal carotenoid levels as they relate to visual field function in patients prescribed a macular pigment-containing medical food (Lumega-Z), in combination with a topical carbonic anhydrase inhibitor.

NCT ID: NCT04647929 Withdrawn - Clinical trials for Primary Congenital Glaucoma

Comparison of Surgical Treatment Options for Primary Congenital and Developmental Glaucomas

STOP-Glaucoma
Start date: December 1, 2020
Phase: N/A
Study type: Interventional

Newborn and children can be affected by two subgroups of this disease: (1) primary congenital glaucoma (PCG) or (2) developmental glaucoma (DG). The primary aim of this study is to compare the Santen PRESERFLO implant to trabeculectomy in PCG and DG patients as second surgery after failed trabeculotomy or goniotomy.

NCT ID: NCT04563559 Withdrawn - Cataract Surgery Clinical Trials

PREFERENTIAL Study

Start date: November 2020
Phase: Phase 2/Phase 3
Study type: Interventional

To determine patient preference for the dexamethasone insert or topical prednisolone therapy through at Day 45 as measured by - Modified COMTOL survey.

NCT ID: NCT04433702 Withdrawn - Glaucoma Clinical Trials

Effect of Negative Pressure on Pattern Electroretinography Readings

Start date: October 1, 2020
Phase: N/A
Study type: Interventional

Glaucoma is a leading cause of blindness worldwide. Intraocular pressure (IOP) remains the only modifiable risk factor for glaucoma. Without sufficient IOP lowering therapy, glaucoma induces retinal ganglion cell death and visual field loss. Pattern electroretinography (pERG) measurements directly correlate with retinal ganglion cell (RGC) signaling, providing an objective, repeatable, and non-invasive assessment of RGC function. The purpose of the study is to investigate the pERG changes associated with acute IOP reduction using the Mercury™ Multi-Pressure Dial (MPD). 10 patients will be enrolled. These subjects will have a best corrected visual acuity of 20/40 or better in both eyes and an established diagnosis of one of either mild/moderate OAG (open-angle glaucoma), OHT (ocular hypertension), or glaucoma suspect. Both eyes will be enrolled in the study. The study eye will receive a standardized 10 mmHg decrease in periorbital pressure via the Mercury™ Multi-Pressure Dial (MPD), and the fellow/control eye will receive no (zero) pressure application. Total google wear time will be 4.5 hours. Serial pERG measurements will be taken before, immediately after, and 2 hours after negative pressure application.

NCT ID: NCT04334499 Withdrawn - Glaucoma Clinical Trials

Mitochondrial DNA in Vitreous Fluid and Blood in Patients With Eye Disease or Ocular Trauma.

Start date: February 21, 2020
Phase:
Study type: Observational

This study is to characterize mitochondrial DNA (mtDNA) populations in adults with eye injuries and eye diseases. The eye exam is often hindered by the clouding of tissues involved in injury or disease. This protocol examines the use of mtDNA populations as indicators of developing inflammation and resolution of injury. This may be used to provide proactive treatment or define appropriate treatment needs beyond the indications of an ophthalmological exam.

NCT ID: NCT04202510 Withdrawn - Open Angle Glaucoma Clinical Trials

IOP and Medication Reduction in MIGS Procedures

Start date: January 6, 2020
Phase: N/A
Study type: Interventional

The primary objective of this research is to compare the efficacy of trabecular minimally invasive glaucoma surgery (MIGS) devices (iStent vs iStent Inject vs Hydrus) for intra ocular pressure (IOP) and anti-glaucoma medication reduction in open angle glaucoma.

NCT ID: NCT04064918 Withdrawn - Clinical trials for OHT - Ocular Hypertension

Effects of Netarsudil and Timolol on Retinal Blood Vessel Density and Visual Acuity

Start date: December 2021
Phase: N/A
Study type: Interventional

The purpose of this research study is to compare the effect of Netarsudil and Timolol on eye pressure and blood vessels of the back of the eye.

NCT ID: NCT04005079 Withdrawn - Ocular Hypertension Clinical Trials

Pilocarpine After Combined Cataract/Trabectome Surgery

PACCT
Start date: June 5, 2019
Phase: Phase 3
Study type: Interventional

Combined cataract + trabectome surgery is a surgery designed to help lower the intraocular pressure (pressure in the eye) and hopefully reduce the need for topical drops, progression of glaucoma, and/or further glaucoma surgeries. The purpose of this study is to assess whether using pilocarpine, a medication which is FDA approved to induce miosis, (in other words cause the pupil to constrict or become smaller) provides additional benefit to the success of Trabectome and cataract surgery.